PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, ...

Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 ...

The International Federation of Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief ...

BRL Medicine raised $27 million in a Series B+ round, led by CSPC Fund, to advance its gene and cell therapies for genetic ...

Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on ...

The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...

Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Roche’s Phase III SKYSCRAPER-01 trial missed its primary endpoint, with tiragolumab combined with Tecentriq failing to ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

US central nervous system (CNS) disorders specialist Axsome Therapeutics (Nasdaq: AXSM) today released encouraging late-stage ...

Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money ...